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 Abstract 
 Background: Cystatin C (CysC) is an alternative marker to creatinine for estimation of the glo-
merular filtration rate (GFR). Hormones such as thyroid hormones and glucocorticoids are 
known to have an impact on CysC. In this study, we examined the effect of growth hormone 
(GH) on CysC in patients with acromegaly undergoing transsphenoidal surgery.  Methods: 
Creatinine, CysC, GH and insulin-like growth factor-1 (IGF-1) were determined in 24 patients 
with acromegaly before and following transsphenoidal surgery. Estimated GFR was calculated 
using the Chronic Kidney Disease Epidemiology Collaboration formula.  Results: In all patients, 
surgical debulking resulted in decreased clinical disease activity and declining GH/IGF-1 lev-
els. Postoperatively, biochemical cure was documented in 20 out of 24 patients. Creatinine 
levels (mean ± SEM) increased from 72 ± 3 to 80 ± 3 μmol/l (p = 0.0004) and concurrently, 
estimated GFR decreased from 99 ± 3 to 91 ± 3 ml/min (p = 0.0008). In contrast to creatinine, 
CysC levels decreased from 0.72 ± 0.02 to 0.68 ± 0.02 mg/l (p = 0.0008).  Conclusions: Our 
study provides strong evidence for discordant effects of GH on creatinine and CysC in patients 
with acromegaly undergoing transsphenoidal surgery, thus identifying another hormone that 
influences CysC independent of renal function.  © 2013 S. Karger AG, Basel 
 Introduction 
 Cystatin C (CysC) is an alternative marker to creatinine for estimation of the glomerular 
filtration rate (GFR), and formulas combining both CysC and creatinine are increasing in 
popularity  [1] . CysC is a sensitive indicator of GFR, as it is freely filtered by glomeruli and 
almost completely reabsorbed and catabolized by tubular epithelial cells  [2] . As compared to 
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creatinine, CysC is less dependent on age and gender  [3, 4] . It is considered superior for 
detection of mild renal dysfunction  [5] , and for prediction of cardiovascular risk and overall 
mortality beyond that provided by the GFR  [6] . The latter may not just be due to differences 
in renal handling of creatinine and CysC, but also due to differences in tissue origin and 
production rates of the two compounds. Indeed, CysC has been found to increase with obesity 
 [3, 7, 8] , to rise in proportion to the number of metabolic syndrome components, and to be 
associated with insulin resistance  [9, 10] independent of the GFR. 
 However, non-GFR determinants of CysC remain poorly defined, as they mainly derive 
from cross-sectional studies, and associations are notoriously subject to confounding  [3, 11] . 
Only few intervention studies have addressed potentially non-GFR-dependent CysC-influ-
encing variables, and these often have failed to show an impact of factors such as changes in 
dietary protein intake and inflammation on CysC  [12, 13] . 
 It has been shown that CysC may be influenced by hormones independent of renal 
function. Triiodothyronine stimulates the production of CysC in vitro  [14, 15] , and thyroid 
hormones increase its levels in vivo  [15–17] . Moreover, CysC production is stimulated by 
dexamethasone in vitro  [14, 18] and by pharmacological doses of glucocorticoids in vivo  [19] . 
The effect of growth hormone (GH) on CysC is as yet unknown, but is of great interest because 
excessive GH production as found in acromegaly not only causes pathognomonic clinical 
signs, but also leads to lower creatinine levels and an increased GFR  [20] . Furthermore, acro-
megaly is associated with insulin resistance, hyperglycemia and reduction in life expectancy 
mainly due to cardiovascular disease. Acromegaly is usually caused by a pituitary adenoma, 
and the main goal of treatment is correction of GH excess, often achieved by transsphenoidal 
removal of the tumor. The aim of this interventional study was to examine the effect of GH 
excess and its correction by surgery on CysC and creatinine levels in patients with newly diag-
nosed acromegaly.
 Methods 
 Patients 
 Twenty-nine consecutive patients with newly diagnosed acromegaly, referred to the 
University Hospital Zurich between 2006 and 2009, were considered eligible for this study, 
which was approved by the local ethics committee and conducted in accordance with the 
Helsinki declaration. Twenty-four subjects (10 female/14 male, aged 28–76 years) gave 
written informed consent and were included in this prospective case series. Diagnosis of 
acromegaly was based on typical clinical findings, elevated insulin-like growth factor-1 
(IGF-1) concentrations, and non-suppressible GH during a 75-gram oral glucose tolerance 
test. In all patients, GH excess was caused by a pituitary adenoma. Adenoma size (in mm 3 ) 
estimation and details of the surgical procedure have been reported elsewhere  [21] . The 
initial tumor size ranged from 50 to 5,091 mm 3 (median 1,844). Patients underwent intraop-
erative MRI-guided transsphenoidal surgery as primary treatment for acromegaly, performed 
by the same surgeon. One patient had undergone previous surgery 17 years ago for prolac-
tinoma with incomplete tumor resection. Clinical examination and laboratory investigations 
were performed before surgery and at a postoperative follow-up visit 22–124 days (median 
88) after surgery. None of the patients suffered from overt central hypothyroidism or hypo-
cortisolism requiring replacement therapy, neither before nor after surgery. Thyroid-stimu-
lating hormone and adrenocorticotropic hormone deficiency were excluded by normal free 
thyroxine and morning cortisol levels, respectively. Still, at the time of evaluation, 1 patient 
had received levothyroxine before surgery, and another patient was prescribed hydrocor-
tisone after the operation for safety reasons. 
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 Biochemical Analyses 
 Blood samples were drawn after overnight fasting. IGF-1 was determined by an 
in-house radioimmunoassay, as described in Goede et al.  [16] , and GH by an immunoradio-
metric assay (hGH-RIACT; CIS Bio International, Oris Industries, Gif-Sur-Yvette, France). 
Fasting plasma glucose was measured on a Roche-Hitachi Modular Clinical Chemistry 
analyzer using commercial tests from Roche Diagnostics. Insulin was determined by a 
solid-phase radioimmunoassay (CIS Bio International, Oris Industries). Homeostasis mo-
del assessment (HOMA) was used to estimate insulin resistance. CysC was measured using 
an immunologic turbidimetric assay (Cobas Integra 800 system; Roche Diagnostics, 
Rotkreuz, Switzerland) with DAKO reagents (DAKO Diagnostics, Zug, Switzerland; normal 
range 0.53–0.95 mg/l, coefficient of variation 5.9% at 0.97 mg/l). Creatinine was measured 
with the kinetic Jaffe reaction (Hitachi P-Modular system; Roche Diagnostics). Estimated 
GFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) formula, which seems more accurate than the widely used Modification of Diet in 
Renal Disease Study equation, especially at an estimated GFR >60 ml/min/1.73 m 2  [22] . 
The CKD-EPI formula, expressed as a single equation, is GFR = 141 × min(Scr/κ,1) α × 
max(Scr/κ,1) –1.209 × 0.993 Age × 1.018 [if female] × 1.159 [if black], where Scr is serum 
creatinine (mg/dl), κ is 0.7 for females and 0.9 for males, α is –0.329 for females and –0.411 
for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of 
Scr/κ or 1.
 Statistical Analysis 
 Data are presented as means ± SEM and were normally distributed using the Kolmogorov-
Smirnov test. Accordingly, values before and after surgery were examined using Student’s 
paired t test, and values between genders were compared using an unpaired t test. Corre-
lation coefficients were assessed using Pearson’s correlation formula. Statistical analyses 
were conducted using STATA SE10 software (StataCorp, College Station, Tex., USA). p values 
<0.05 were considered statistically significant. 
 Results 
 Body Mass Index, Blood Pressure, Heart Rate 
 After surgery, body mass index (BMI), systolic and diastolic blood pressure, heart rate, 
and pulse pressure decreased considerably ( table 1 ).
 Growth Hormone and Insulin-Like Growth Factor-1 
 In all 24 patients, surgical debulking resulted in decreased clinical disease activity and 
declining GH basal and IGF-1 levels. GH nadir levels of <1 μg/l were documented either in a 
random blood sample or during an oral glucose tolerance test in 20 of the 24 patients, 
consistent with complete adenoma removal. 
 Creatinine, Estimated GFR, and CysC 
 Creatinine levels increased (from 72 ± 3 to 80 ± 3 μmol/l, p = 0.0004;  fig. 1 ), and the esti-
mated GFR declined accordingly (from 99 ± 3 to 91 ± 3 ml/min, p = 0.0008), whereas CysC 
levels decreased (from 0.72 ± 0.02 to 0.68 ± 0.02 mg/l, p = 0.0008). The (inverse) correlation 
between CysC and estimated GFR reached statistical significance only after (r = –0.44, p = 
0.03), but not before surgery (r = –0.19, p = 0.37). CysC was higher in men than in women 
before surgery (0.75 ± 0.03 vs. 0.66 ± 0.02 mg/l, p = 0.03), but similar in both groups after 
surgery (0.70 ± 0.03 vs. 0.65 ± 0.02 mg/l, p = 0.19). Creatinine levels were higher in men than 
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Table 1.  Clinical and biochemical parameters before and after surgery (mean ± SEM)
Before surgery After surgery p values 
(before vs. after)
BMI 28.1 ± 0.1 27.6 ± 0.1 0.02
Systolic blood pressure, mm Hg 139.2 ± 3.5 125.5 ± 2.4 <0.0001
Diastolic blood pressure, mm Hg 82.8 ± 1.8 78.2 ± 2.0 0.03
Pulse pressure, mm Hg 56 ± 3 47 ± 2 0.0007
Heart rate, bpm 76 ± 2 66 ± 2 0.0007
GH, μg/l 26.3 ± 5.2 2.5 ± 0.6 0.0001
IGF-1, μg/l 594 ± 34 192 ± 12 0.0001
Phosphate, mmol/l 1.36 ± 0.04 1.05 ± 0.02 <0.0001
Sodium, mmol/l 140.4 ± 0.5 140.9 ± 0.5 NS
Potassium, mmol/l 3.9 ± 0.1 4.0 ± 0.1 NS
Fasting plasma glucose, mmol/l 5.7 ± 0.2 5.1 ± 0.2 0.002
HOMA index 7.4 ± 0.9 3.3 ± 0.4 0.0001
CysC, mg/l 0.72 ± 0.02 0.68 ± 0.02 0.0008
Creatinine, μmol/l 72 ± 3 80 ± 3 0.0004
GFR, ml/min 99 ± 3 91 ± 3 0.0008
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 Fig. 1. Creatinine ( a ) (p = 0.0004) and CysC ( b ) (p = 0.0008) before and after surgery. Males = Circles, solid 
lines; females = triangles, dashed lines. 
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in women both before (77 ± 3 vs. 63 ± 3 μmol/l, p = 0.03) and after surgery (88 ± 3 vs. 68 ± 2 
μmol/l, p < 0.0001). CysC did not correlate with age, as opposed to creatinine (p = 0.01 before 
and 0.04 after surgery). 
 Electrolytes and Glucose Homeostasis 
 Fasting plasma glucose and phosphate were high at baseline and decreased significantly 
following surgery, whereas sodium and potassium remained unchanged. Insulin sensitivity 
improved after surgery ( table 1 ). Two patients with type 2 diabetes on insulin therapy before 
surgery were excluded from glucose homeostasis assessment; postoperatively, one of them 
had normal glucose levels without medication, and insulin was replaced by oral antidiabetic 
treatment in the other patient. CysC correlated neither with fasting plasma glucose, HOMA 
index nor BMI.
 Discussion 
 In our patients with acromegaly, surgical correction of GH excess resulted in the expected 
increase in creatinine levels, but decreased CysC levels, pointing out discordant effects of GH 
excess on creatinine and CysC. Given the known GFR increase caused by GH excess, CysC could 
have been expected to be low at baseline and to rise after surgery. 
 Opposite effects on plasma creatinine and CysC have been shown with thyroid hormones 
 [15–17] . Discordant results of these plasma markers have also been found in patients receiving 
high-dose glucocorticoids as immunosuppressive treatment by some  [19] , but not all inves-
tigators  [23] . GH appears to be a further hormone which affects CysC independent of renal 
function. 
 Our observation that GH excess increases CysC is in accordance with the findings during 
the physiological condition of normal puberty, where GH activity is enhanced. In the NHANES 
study, CysC levels were found to peak at the age of 12 in females, and at the age of 14 in males, 
apparently in the absence of changes in the GFR. Since CysC levels rose in parallel with peak 
height velocity, the authors proposed that CysC levels could be affected by growth in adoles-
cents, and that the age-related variation in CysC levels was likely related to variation in CysC 
production  [24] .
 We cannot exclude indirect effects of GH to be responsible for the observed changes of 
CysC levels, e.g. via changes in body composition, insulin resistance, or the generation and 
action of IGF-1 and triiodothyronine. It could be speculated that acromegaly-associated 
insulin resistance would be consistent with higher CysC levels before surgery. An association 
of CysC with insulin resistance has been found in several studies  [9, 10] ; however, in our 
patients, CysC did not correlate with the HOMA index. 
 Non-GFR-dependent effects of GH on CysC are possibly more readily observed in patients 
with otherwise unimpaired renal function. The (negative) correlation between CysC and esti-
mated GFR (significant only after surgery) is noteworthy, given that the ‘true’ GFR of most of 
our acromegalic patients presumably still remained in a ‘creatinine-blind’ range  and could 
not be reliably estimated by plasma-derived values, neither by the CKD-EPI formula  [22] nor 
by CysC.
 A major advantage of our study is GH excess correction solely by surgery, with most 
patients being cured. Therefore, results of creatinine and CysC were not confounded by drugs 
such as somatostatin receptor analogues, which may have renal effects. Measurement of 
creatinine and CysC in the same blood samples ensured the same GH status as well as other 
potential determinants of these parameters. 
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 Our study has several limitations. Firstly, GFR was only estimated from (creatinine-
based) calculations, and not directly measured by inulin clearance or by isotopes, so the ‘true’ 
GFR was not determined. However, we tried to estimate GFR with the CKD-EPI formula, which 
operates best at a higher GFR (>60 ml/min)  [22, 25] . Secondly, we did not analyze body 
composition (decreased BMI during early postsurgical follow-up is most likely dominated by 
the loss of extracellular water and muscle mass). Finally, we only measured free thyroxine 
levels in our patients (to exclude hypothyroidism before or after surgery), but free triiodo-
thyronine was not measured, which is increased by GH and may have an impact on both CysC 
levels and renal function. 
 To our knowledge, this is the first study providing strong evidence for a differential effect 
of GH on creatinine and CysC, two plasma or serum markers of renal function. Thus, a further 
hormone is being identified, which influences CysC independent of renal function. 
 Disclosure Statement 
 The authors have no conflict of interest to declare.
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